Nothing Special   »   [go: up one dir, main page]

MX2013012542A - Compuestos de amida y aplicacion farmaceutica para el mismo. - Google Patents

Compuestos de amida y aplicacion farmaceutica para el mismo.

Info

Publication number
MX2013012542A
MX2013012542A MX2013012542A MX2013012542A MX2013012542A MX 2013012542 A MX2013012542 A MX 2013012542A MX 2013012542 A MX2013012542 A MX 2013012542A MX 2013012542 A MX2013012542 A MX 2013012542A MX 2013012542 A MX2013012542 A MX 2013012542A
Authority
MX
Mexico
Prior art keywords
amide compound
pharmaceutical application
application therefor
therefor
pharmaceutical
Prior art date
Application number
MX2013012542A
Other languages
English (en)
Inventor
Masahiro Yokota
Makoto Shiozaki
Katsuya Maeda
Takaki Maeba
Masayuki Kotoku
Kazuyuki Hirata
Noriyoshi Seki
Hiroshi Yamanaka
Takayuki Sakai
Shintaro Hirashima
Shingo Obika
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2013012542A publication Critical patent/MX2013012542A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula [l-W]: (Ver Formula) en donde cada símbolo es como se define en la descripción, o una de sus sales farmacéuticamente aceptables.
MX2013012542A 2011-04-28 2012-04-27 Compuestos de amida y aplicacion farmaceutica para el mismo. MX2013012542A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011100331 2011-04-28
US201161482418P 2011-05-04 2011-05-04
PCT/JP2012/061352 WO2012147916A1 (ja) 2011-04-28 2012-04-27 アミド化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
MX2013012542A true MX2013012542A (es) 2013-11-20

Family

ID=47072428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012542A MX2013012542A (es) 2011-04-28 2012-04-27 Compuestos de amida y aplicacion farmaceutica para el mismo.

Country Status (19)

Country Link
US (3) US8604069B2 (es)
EP (2) EP2927217B1 (es)
JP (2) JP5902029B2 (es)
KR (1) KR101964478B1 (es)
CN (1) CN103619824B (es)
AR (1) AR086156A1 (es)
AU (1) AU2012248223B2 (es)
BR (1) BR112013027670B1 (es)
CA (1) CA2833493C (es)
CO (1) CO6801761A2 (es)
HK (1) HK1215948A1 (es)
IL (1) IL228979A (es)
MX (1) MX2013012542A (es)
PE (1) PE20141637A1 (es)
RU (1) RU2013152788A (es)
SG (1) SG194526A1 (es)
TW (1) TWI532728B (es)
WO (1) WO2012147916A1 (es)
ZA (1) ZA201307977B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013012542A (es) * 2011-04-28 2013-11-20 Japan Tobacco Inc Compuestos de amida y aplicacion farmaceutica para el mismo.
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
MX2014014614A (es) 2012-05-31 2015-02-12 Phenex Pharmaceuticals Ag Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano ror [gamma).
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
WO2014062658A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
EA201590750A1 (ru) 2012-10-16 2015-09-30 Янссен Фармацевтика Нв СВЯЗАННЫЕ С ФЕНИЛОМ ХИНОЛИНИЛОВЫЕ МОДУЛЯТОРЫ RORγT
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
CN105121430B (zh) 2012-12-06 2017-06-16 葛兰素集团有限公司 用于治疗自身免疫性和炎性疾病的类维生素A相关的孤儿受体γ(RORγ)的调节剂
CN104870612B (zh) * 2012-12-17 2017-09-12 默克专利股份有限公司 液晶显示器和具有垂面配向的液晶介质
JP6427491B2 (ja) * 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
WO2015035032A1 (en) * 2013-09-05 2015-03-12 Boehringer Ingelheim International Gmbh Bicylic compounds as modulators of rorgamma
BR112016008158A2 (pt) * 2013-10-15 2017-10-03 Janssen Pharmaceutica Nv Moduladores de ror-gama-t de quinolinila ligados a metileno
CN105848483A (zh) 2013-10-15 2016-08-10 詹森药业有限公司 RORγt 的喹啉基调节剂
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
CN105873439A (zh) 2013-10-15 2016-08-17 詹森药业有限公司 RORγt的烷基连接的喹啉基调节剂
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
WO2015129853A1 (ja) * 2014-02-27 2015-09-03 東レ株式会社 環状アミン誘導体及びその医薬用途
PE20170137A1 (es) 2014-05-28 2017-03-05 Glaxosmithkline Ip Dev Ltd Nuevos compuestos
WO2015180613A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
CA2950211C (en) 2014-05-28 2023-02-07 Glaxosmithkline Intellectual Property Development Limited 3-((piperazin-1-yl)methyl)-phenyl amide derivatives and their use as retinoid-related orphan receptor gamma (ror.gamma.) modulators
SG11201702362SA (en) 2014-10-14 2017-04-27 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
SI3231793T1 (sl) * 2014-12-12 2020-07-31 Japan Tobacco Inc. Spojine dihidropirimidin-2-ona in njihove medicinske uporabe
CA2973185C (en) 2015-01-08 2021-02-16 Advinus Therapeutics Limited Bridgehead nitrogen bicyclic inhibitors/modulators of retinoic acid-related orphan receptor gamma (ror.gamma.)
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
CN108463458B (zh) 2015-11-20 2022-02-01 生命医药有限责任公司 ROR-γ的调节剂
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
TWI691486B (zh) 2016-01-29 2020-04-21 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
JP2020528904A (ja) 2017-07-24 2020-10-01 ヴァイティー ファーマシューティカルズ，エルエルシー ＲＯＲγの阻害剤
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
JPWO2019022235A1 (ja) 2017-07-27 2020-05-28 東レ株式会社 円形脱毛症の治療剤又は予防剤
TW201910312A (zh) * 2017-07-28 2019-03-16 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
TW201920137A (zh) * 2017-08-31 2019-06-01 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
BR112020013438A2 (pt) 2018-01-31 2020-12-01 Toray Industries, Inc. derivado de amina cíclico, medicamento, antagonista de receptor órfão gama relacionado a retinoide, e, agentes terapêuticos ou agentes preventivos para uma doença autoimune, para psoríase ou alopecia areata, para uma doença alérgica, para dermatite alérgica e para dermatite de contato ou dermatite atópica
KR20200126973A (ko) 2018-02-28 2020-11-09 니뽄 다바코 산교 가부시키가이샤 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768840A (en) * 1952-11-28 1957-02-20 Cassella Farbwerke Mainkur Ag Compounds containing a cyclopentyl ring
US5464860A (en) 1988-11-30 1995-11-07 Novapharme N(pyrazol-3-yl) benzamides and pharmaceutical compositions
FR2639636B1 (fr) 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
US5258397A (en) 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
JPH09278741A (ja) * 1996-04-10 1997-10-28 Tanabe Seiyaku Co Ltd フェノール誘導体
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JP3237608B2 (ja) * 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
DK1037880T3 (da) 1997-12-11 2004-11-15 Janssen Pharmaceutica Nv Anilider som retinsyremimetika
AU2002367426A1 (en) 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Neurotrophic factor production/secretion accelerator
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
CN101014578B (zh) * 2004-09-16 2011-01-19 安斯泰来制药有限公司 三唑衍生物或其盐
WO2010004972A1 (ja) 2008-07-08 2010-01-14 第一三共株式会社 含窒素芳香族ヘテロシクリル化合物
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
EA201100921A1 (ru) 2008-12-08 2011-12-30 Эроскрин С.А. Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
MX2013012542A (es) * 2011-04-28 2013-11-20 Japan Tobacco Inc Compuestos de amida y aplicacion farmaceutica para el mismo.

Also Published As

Publication number Publication date
IL228979A (en) 2015-03-31
WO2012147916A1 (ja) 2012-11-01
HK1215948A1 (zh) 2016-09-30
TWI532728B (zh) 2016-05-11
IL228979A0 (en) 2013-12-31
EP2927217B1 (en) 2018-01-17
RU2013152788A (ru) 2015-06-10
CA2833493C (en) 2020-06-02
PE20141637A1 (es) 2014-11-20
AU2012248223B2 (en) 2017-03-02
CN103619824B (zh) 2015-09-09
JP2016147880A (ja) 2016-08-18
JP2012236822A (ja) 2012-12-06
NZ618372A (en) 2015-06-26
US20160346256A1 (en) 2016-12-01
CN103619824A (zh) 2014-03-05
BR112013027670A2 (pt) 2016-12-27
KR20140021614A (ko) 2014-02-20
ZA201307977B (en) 2014-07-30
US20140296306A1 (en) 2014-10-02
US20120322837A1 (en) 2012-12-20
JP5902029B2 (ja) 2016-04-13
KR101964478B1 (ko) 2019-04-01
CA2833493A1 (en) 2012-11-01
EP2927217A1 (en) 2015-10-07
AU2012248223A1 (en) 2013-12-19
AR086156A1 (es) 2013-11-20
BR112013027670B1 (pt) 2021-11-09
TW201249813A (en) 2012-12-16
EP2719690A1 (en) 2014-04-16
CO6801761A2 (es) 2013-11-29
US8604069B2 (en) 2013-12-10
EP2719690A4 (en) 2014-12-31
SG194526A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
PH12015500900A1 (en) A stabilized pemetrexed formulation
EP2746283A4 (en) PYRIMIDOPYRIMIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES
IN2015DN01035A (es)
MX2015001246A (es) Ibrutinib deuterado.
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
HK1197242A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines -56--4h-[13]
MX2014002552A (es) Compuesto pirazol y su uso farmaceutico.
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
HK1198586A1 (zh) -二氟甲基- -二氫- 噁嗪- -胺衍生物
GB201305247D0 (en) Amide Compounds
IL233055A0 (en) (1r,r4) 7-oxo-2-azabicyclo [2.2.2] oct-5-ene and its derivatives
PH12015501146A1 (en) Hydantoin derivative
IL221737A (en) Its compound or salt, a pharmaceutical preparation containing it and its uses
IL230655A0 (en) Derivatives n-hetero-converted in the amide ring, preparations containing them and their uses
EP2701718A4 (en) LANTIBIOTIC NAI-802, PHARMACEUTICALLY ACCEPTABLE SALTS, ITS COMPOSITIONS, AND USES THEREOF
PL394759A1 (pl) Fotochromowe pochodne N-(2,6-dimetoksypirymidyn-4-ilo)benzenosulfonamidu i sposób ich otrzymywania
TH122547B (th) สารประกอบอะซาไบไซโคล[3.2.0]เฮปท์-3-อิลชนิดใหม่,กรรมวิธีสำหรับการ เตรียมสิ่งเหล่านี้และองค์ประกอบทางเภสัชกรรมที่มีสิ่งเหล่านี้